Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in ...

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk ...

Already USFDA-approved, under-the-skin jab can be administered in just seven minutes to the patient. This is dramatic cut ...

Immmunotherapy-based treatments demonstrate effectiveness and safety profiles consistent with clinical trials in real-world setting.

Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report ...

Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.

To our knowledge, the SOGUG-AUREA trial showed, for the first time, that the combination of atezolizumab with split doses of cisplatin and gemcitabine was effective and safe for patients with mUC ,” ...

Elicio's mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key ...

Experts debate which patients with stage III dMMR colon cancer will benefit from the two treatment approaches.

Topline data were announced from a phase 3 trial evaluating zanzalintinib in combination with atezolizumab in patients with previously treated non-microsatellite instability (MSI)-high metastatic ...

The recent data readout from studies on zanzalintinib has been positive. In June 2025, EXEL announced positive top-line results from the late-stage STELLAR-303 study. This phase III study is a global, ...

Exelixis' revenue growth through cabozantinib, mixed trial updates on zanzalintinib, and potential market shifts following ...